Autoimmune Disease Clinical Trials: RA, Lupus, and MS

Autoimmune disease treatment is being reshaped by three converging advances: selective JAK inhibitors that offer targeted oral therapy, CAR-T cell approaches borrowed from cancer that may offer durable remissions, and bispecific antibodies that simultaneously neutralize multiple inflammatory pathways. For the 24 million Americans with autoimmune conditions, the current trial landscape offers genuinely new categories of treatment.

Important: This is not medical advice. Never stop or change your current medications without talking to your doctor. Talk to your doctor about whether a clinical trial is right for you.

CAR-T for Autoimmune Diseases

Perhaps the most exciting development in autoimmune research is the adaptation of CAR-T cell therapy — a technology that revolutionized blood cancer treatment — for severe autoimmune diseases:

• How it works: A patient's T cells are collected, genetically engineered to target CD19+ B cells (which produce the autoantibodies attacking the body), and infused back. The treatment eliminates the rogue B cells driving the autoimmune attack.
• Lupus breakthroughs: Early case series showed complete remissions in severe lupus patients who had failed multiple therapies. Patients were able to stop all immunosuppressive medications.
• Expanding indications: Trials are now testing CAR-T in systemic sclerosis (scleroderma), inflammatory myopathies, and refractory rheumatoid arthritis.
• Safety profile: Autoimmune CAR-T appears to cause milder cytokine release syndrome than cancer CAR-T, likely because the B cell burden is lower.

Next-Generation JAK Inhibitors

JAK inhibitors transformed autoimmune treatment by offering oral alternatives to injectable biologics. Current research is addressing the safety signals seen with first-generation drugs:

• Selective targeting: Newer drugs target specific JAK subtypes (TYK2, JAK1-selective) to reduce off-target effects while maintaining efficacy
• Deucravacitinib (TYK2): Approved for psoriasis, now in trials for lupus, psoriatic arthritis, and inflammatory bowel disease
• Topical formulations: JAK inhibitor creams for skin-dominant autoimmune conditions, avoiding systemic exposure
• Combination strategies: Testing JAK inhibitors alongside other targeted therapies for refractory disease

Bispecific Antibodies

Bispecific antibodies can bind two different targets simultaneously, potentially offering greater efficacy than single-target biologics:

• Dual cytokine neutralization (e.g., blocking both IL-17 and TNF, or both IL-4 and IL-13)
• Simultaneous B cell and T cell modulation
• Tissue-targeted delivery that concentrates the drug in inflamed joints or gut rather than suppressing the entire immune system

Recruiting Autoimmune Disease Trials

Disease-Specific Highlights

Multiple Sclerosis

MS trials are testing Bruton's tyrosine kinase (BTK) inhibitors that cross the blood-brain barrier, remyelination therapies that aim to repair nerve damage, and stem cell transplant for aggressive relapsing MS. The field is also exploring whether treatment can be safely de-escalated after long-term remission.

Inflammatory Bowel Disease (Crohn's and Colitis)

IBD trials feature IL-23 inhibitors (risankizumab, mirikizumab), sphingosine-1-phosphate receptor modulators (ozanimod), and combination biologic strategies for patients who have failed single-agent therapy. Microbiome-based treatments including fecal microbiota transplant are also in trials.

Lupus

Lupus has historically been one of the hardest autoimmune diseases to treat. Current trials include anti-interferon therapies, B cell-depleting strategies, calcineurin inhibitors for lupus nephritis, and the CAR-T approaches described above.

Frequently Asked Questions